

# MAGLUMI f-PSA (CLIA)



130201005M



100



**Shenzhen New Industries  
Biomedical Engineering Co., Ltd**  
4/F, Wearnes Tech Bldg,  
Science & Industry Park,  
Nanshan, Shenzhen, 518057 CHINA  
Tel. + 86-755-86028224  
Fax. + 86-755-26654850



**Lotus Global Co., Ltd**  
15 Alexandra Road  
London  
UK  
NW8 0DP  
Tel. + 44-20-75868010  
Fax. + 44-20-79006187



**FOR PROFESSIONAL USE ONLY**  
Store at 2-8 °C



**COMPLETELY READ THE INSTRUCTIONS BEFORE  
PROCEEDING**

en

## SYMBOLS EXPLANATIONS



Authorized Representative in the European community



Manufacturer



Consult instructions for use



Contents of kit



In vitro diagnostic medical device




Batch code



Catalogue number



Use by



Temperature limitation  
(store at 2-8°C)



Sufficient for



Keep away from sunlight



Keep upright for storage

## INTENDED USE

The kit has been designed for the quantitative determination of Free Prostate Specific Antigen (f-PSA) in human serum.

The method can be used for samples over the range of 0.05-60ng/ml.

The test has to be performed on the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI (Including Maglumi 600, Maglumi 1000, Maglumi 1000 Plus, Maglumi 2000, Maglumi 2000 Plus, Maglumi 3000 and Maglumi 4000).

## SUMMARY AND EXPLANATION OF THE TEST

PSA- a serine protease- is a secretory enzyme produced by the epithelium of the prostatic duct. In the healthy organism, PSA is a liquefacient of seminal plasma.

As soon as PSA reaches the bloodstream, it is bound and inactivated by protease inhibitors. The most important inhibitors are a1- antichymotrypsin (ACT) and a2-macroglobulin (AMG). AMG completely encompasses the PSA molecule so that PSA thus bound is no longer detectable in serum. The PSA-ACT complex, however, allows for the detection of the tumor marker.

Since PSA is an organ-specific marker, its determination is increasingly used in primary diagnosis and together with digital-rectal examinations in the screening of high-risk groups, mainly in man above 50 years.

Benign disorders such as prostatic hyperplasia or inflammatory processes in adjacent urogenital tissues may also lead to an increase in PSA serum levels thus reducing the specificity of the marker.

The ratio between the PSA-ACT complex and free PSA is different in BPH and prostate carcinoma (PCA). Therefore, discrimination between benign and malignant disease is improved by the determination of the f/t PSA ratio.

However, the exact f/t PSA ratio cannot be determined unless total PSA is completely, i.e. equimolarly, detected by the antibodies used in the assay. It is only this way that the f/t PSA quotient may be expressed as a constant cut-off value.

## PRINCIPLE OF THE TEST

Sandwich immunoluminometric assay;

Use an anti-f-PSA monoclonal antibody to label ABEI and use another monoclonal antibody to coat magnetic microbeads. Sample, Calibrator or Control with ABEI Label, buffer and magnetic microbeads are mixed thoroughly and incubated at 37°C, forming a sandwich; after sediment in a magnetic field, decant the supernatant and then cycle washing for 1 time. Subsequently, the starter reagents are added and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as RLU within 3 seconds and is proportional to the concentration of f-PSA present in samples.



## KIT COMPONENTS

### Material Supplies

Reagent Integral for 100 determinations	
<b>Nano magnetic microbeads:</b> coated with anti-f-PSA monoclonal antibody, contains BSA, 0.2%NaN <sub>3</sub> .	2.5ml
<b>Calibrator Low:</b> bovine serum, 0.2%NaN <sub>3</sub>	2.5ml
<b>Calibrator High:</b> bovine serum, 0.2%NaN <sub>3</sub>	2.5ml
<b>Buffer:</b> contains BSA, 0.2% NaN <sub>3</sub>	10.5ml
<b>ABEI Label:</b> anti-f-PSA monoclonal antibody labeled ABEI, contains BSA, 0.2%NaN <sub>3</sub> .	10.5ml
All reagents are provided ready-to-use.	

Reagent Vials in kit box	
Internal Quality Control: containing BSA, 0.2%NaN <sub>3</sub> . (target value refer to Quality Control Information date sheet)	2.0ml

Internal quality control is only applicable with MAGLUMI system. Instructions for use and target value refer to Quality Control Information date sheet. User needs to judge results with their own standards and knowledge.

#### Accessories Required But Not Provided

MAGLUMI Reaction Module	REF: 630003
MAGLUMI Starter 1+2	REF: 130299004M
MAGLUMI Wash Concentrate	REF: 130299005M
MAGLUMI Light Check	REF: 130299006M

Please order accessories from SNIBE or our representative.



#### Preparation of the Reagent Integral

Before the sealing is removed, gentle and careful horizontal shaking of the Reagent Integral is essential (avoid foam formation!) Remove the sealing and turn the small wheel of the magnetic microbeads compartment to and fro until the color of the suspension has changed into brown. Place the Integral into the reagent area and let it stand there for 30 min. During this time, the magnetic microbeads are automatically agitated and completely resuspended.

**Do not interchange integral component from different reagents or lots!**

#### Storage and Stability

- Sealed: Stored at 2-8°C until the expiry date.
- Opened: Stable for 4 weeks. To ensure the best kit performance, it is recommended to place opened kits in the refrigerator if it's not going to be used on board during the next 12 hours.



- Keep upright for storage



- Keep away from sunlight

## CALIBRATION AND TRACEABILITY

### 1) Traceability

To perform an accurate calibration, we have provided the test calibrators standardized against the WHO International Standard Prostate-Specific Antigen Free NIBSC code: 96/668.

### 2) 2-Point Recalibration

Via the measurement of calibrators, the predefined master curve is adjusted (recalibrated) to a new, instrument-specific measurement level with each calibration.

### 3) Frequency of Recalibration

- After each exchange of lots (Reagent Integral or Starter Reagents).
- Every 4 weeks and/or each time a new Integral is used (recommendation).
- After each servicing of the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI
- If controls are beyond the expected range.
- The room temperature has changed more than 5 °C (recommendation)

## SPECIMEN COLLECTION AND PREPARATION

Sample material: serum  
036130729-V2.2-EN

Collect 5.0ml venous blood into Blood Collection Tube. Standing at room temperature, centrifuging, separating serum part.

The serum sample is stable for up to 12 hours at 2-8°C. More than 12 hours, please packed, -20 °C can be stored for 30 days.

Avoid repeated freezing and thawing, the serum sample can be only frozen and thawed two times. Stored samples should be thoroughly mixed prior to use (Vortex mixer).

If sediments appeared in the specimens, it should be centrifugate before analysis.

Please ask local representative of SNIBE for more details if you have any doubt.

#### Vacuum Tubes

- Blank tubes are recommended type for collecting samples.
- Please ask SNIBE for advice if special additive must be used in sample collecting.

#### Specimen Conditions

- Do not use specimens with the following conditions:
  - heat-inactivated specimens;
  - Cadaver specimens or body fluids other than human serum;
  - Obvious microbial contamination.
- Use caution when handling patient specimens to prevent cross contamination. Use of disposable pipettes or pipette tips is recommended.
- Inspect all samples for bubbles. Remove bubbles with an applicator stick prior to analysis. Use a new applicator stick for each sample to prevent cross contamination.
- Serum specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.

#### Preparation for Analysis

- Patient specimens with a cloudy or turbid appearance must be centrifuged prior to testing. Following centrifugation, avoid the lipid layer (if present) when pipetting the specimen into a sample cup or secondary tube.
- Specimens must be mixed **thoroughly** after thawing by **low** speed vortexing or by gently inverting, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results. Multiple freeze-thaw cycles of specimens should be avoided.
- All samples (patient specimens or controls) should be tested within 3 hours of being placed on board the MAGLUMI System. Refer to the SNIBE service for a more detailed discussion of onboard sample storage constraints.

#### Storage

- If testing will be delayed for more than 8 hours, remove serum from the serum separator, red blood cells or clot. Specimens removed from the separator gel, cells or clot may be stored up to 12 hours at 2-8°C.
- Specimens can be stored up to 30 days frozen at -20°C or colder.

#### Shipping

Before shipping specimens, it is recommended that specimens be removed from the serum separator, red blood cells or clot. When shipped, specimens must be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens must be shipped frozen (dry ice). Do not exceed the storage time limitations identified in this

section of the package insert.

## WARNING AND PRECAUTIONS FOR USERS



- For use in *IN-VITRO* diagnostic procedures only.
- Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

### Safety Precautions

**CAUTION:** This product requires the handling of human specimens.

- Results of the kits are only for clinical reference. For the patient's clinical diagnosis and treatment should be combined with its symptoms, signs, history, other laboratory tests and treatment reaction, and then take them into consideration compositely .
- It may have different results in using different manufacturers reagent for the same sample to detect tumor marker , because of the methodology , specificity of the antibody and so on. To avoid the wrong medicine interpretation, in the process of monitoring tumor, the different reagent testing results should not be directly compared with each other. Suggest the laboratories give test reports to the clinical doctor indicating the reagent characteristics. When the reagent type changed in the series of monitoring, it should be has extra continuity testing and compare with the original reagent results parallelly to determine the baseline value again.
- The calibrators in this kit are prepared from bovine serum products. However, because no test method can offer complete assurance that HIV, Hepatitis B Virus or other infectious agents are absent, even they have passed the tests of HBs-Ag, HIV1/2-Ab, HCV-Ab and so on; These reagents should be considered a potential biohazard and handled with the same precautions as applied to any serum or plasma specimen.
- All samples, biological reagents and materials used in the assay must be considered potentially able to transmit infectious agents. They should therefore be disposed of in accordance with the prevailing regulations and guidelines of the agencies holding jurisdiction over the laboratory, and the regulations of each country. Disposable materials must be incinerated; liquid waste must be decontaminated with sodium hypochlorite at a final concentration of 5% for at least half an hour. Any materials to be reused must be autoclaved using an overkill approach. A minimum of one hour at 121°C is usually considered adequate, though the users must check the effectiveness of their decontamination cycle by initially validating it and routinely using biological indicators.
- It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the OSHA Standard on Blood borne Pathogens<sup>13</sup>. Biosafety Level 214 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- This product contains Sodium Azide; this material and its container must be disposed of in a safe way.
- Safety data sheets are available on request.

### Handling Precautions

- Do not use reagent kits beyond the expiration date.
- Do not mix reagents from different reagent kits.
- Prior to loading the Reagent Kit on the system for the first time, the microbeads requires mixing to re-suspend microbeads that have settled during shipment.

- For microbeads mixing instructions, refer to the KIT COMPONENTS, Preparation of the Reagent Integral section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and sample.
- Over time, residual liquids may dry on the kit surface; please pay attention to the silicon film still exists on the surface of the kit.
- For a detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

## TEST PROCEDURE

To ensure proper test performance, strictly adhere to the operating instructions of the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI. Each test parameter is identified via a RFID tag on the Reagent Integral. For further information please refer to the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI Operating Instructions.

40µl	Sample, calibrator
+80µl	ABEI Label
+80µl	Buffer
+20µl	Nano magnetic microbeads
15min	Incubation
400µl	Cycle washing
3 s	Measurement

## DILUTION

Sample dilution by analyzer is not available in this reagent kit. Samples with concentrations above the measuring range can be diluted manually. After manual dilution, multiply the result by the dilution factor. Please choose applicable diluents or ask SNIBE for advice before manual dilution must be processed

## QUALITY CONTROL

- Observe quality control guidelines for medical laboratories
- Use suitable controls for in-house quality control. Controls should be run at least once every 24 hours when the test is in use, once per reagent kit and after every calibration. The control intervals should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined ranges. Each laboratory should establish guidelines for corrective measures to be taken if values fall outside the range.

## LIMITATIONS OF THE PROCEDURE

### 1) Limitations

Determination of the f/t PSA ratio in serum is only useful for diagnostic and screening purposes prior to the initiation of therapy. So far, no valid clinical results are available for its determination in follow-up. Therapeutic intervention may strongly influence the f/t PSA ratio. Therefore, the a.m. cut-off is no longer applicable. Manipulations at the prostate (e.g. DRE) may also lead to variations in the f/t PSA ratio (1, 3, 6 and 8). F/t PSA rations alone provide no evidence of presence of malignancies; they may be only interpreted in context with the clinical picture and other diagnostic procedures.

### 2) Interfering Substances

No interference with test results is seen by concentrations of bilirubin<65mg/dL, haemoglobin<1.0g/dL or Triglycerides<1500 mg/dL, RF<1500IU/ml.

### 3) HAMA

Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

#### 4) High-Dose Hook

No high-dose hook effect was seen for f-PSA concentrations up to 1000ng/ml.

## RESULTS

### 1) Calculation of Results

The analyzer automatically calculates the f-PSA concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in ng/ml. For further information please refer to the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI Operating Instructions.

### 2) Interpretation of Results

- Results of study in clinical centers with group of individuals, 95% of the results were:  
Male < 1.5ng/ml Female < 0.1ng/ml
- Results may differ between laboratories due to variations in population and test method. If necessary, each laboratory should establish its own reference range.

## PERFORMANCE CHARACTERISTICS

### 1) Precision

Intra-assay coefficient of variation was evaluated on 3 different levels of control serum repeatedly measured 20 times in the same run, calculating the coefficient of variation.

Intra-assay precision			
Control	Mean(ng/ml)	SD(ng/ml)	CV%
Level 1	0.28	0.02	6.37
Level 2	3.02	0.17	5.82
Level 3	13.07	0.71	5.41

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 21 times, calculating the coefficient of variation.

Inter-assay precision			
Control	Mean(ng/ml)	SD(ng/ml)	CV%
Level 1	0.30	0.04	9.62
Level 2	2.96	0.27	9.33
Level 3	13.81	1.36	9.86

### 2) Analytical Sensitivity

The sensitivity is defined as the concentration of f-PSA equivalent to the mean RLU of 20 replicates of the zero standard plus two standard deviations corresponding to the concentration from the standard curve. The sensitivity is typically less than 0.05ng/ml.

### 3) Specificity

The specificity of the f-PSA assay system was assessed by measuring the apparent response of the assay to various potentially cross reactive analytes.

Compound	Concentration	Cross reactivity
Total PSA	100 ng/ml	0.05%
CA19-9	100 ng/ml	0.05%

### 4) Recovery

Consider calibrator high of known concentration as a sample, dilute it by 1:2 ratios with diluents, and measure its diluted concentration for 10 times. Then calculate the recovery of measured concentration and expected concentration. The recovery should be within 90% -110%.

Expected	Mean Measuring	Recovery
18.397ng/ml	17.843 ng/ml	96%

### 5) Linearity

Use f-PSA calibrator to prepare the six-point standard curve, measuring all points' RLU except point A, and then do four-parameter linear fitting in double logarithm coordinate, the absolute linear correlation coefficient(r) should be bigger than 0.9900.

Calibrator Point	Concentration ng/ml	Absolute linear correlation coefficient (r)
A	0	
B	0.5	r=0.9920

C	5
D	10
E	30
F	60

### 6) Method comparison

A comparison of MAGLUMI f-PSA (y) with a commercially available f-PSA test (x) using clinical samples gave the following correlations (ng/ml):

Linear regression

$$y = 0.9959x + 0.0316$$

$$r = 0.9982$$

Number of samples measured: 100

The sample concentrations were between 0.13 and 38.71 ng/ml.

## REFERENCES

- Bossens MMF, Van Straalen JP, De Reijke Tm, Kurth KH, Sanders GTB. Kinetics of Prostate-specific Antigen after Manipulation of the Prostate. *Eur J Cancer* 1995; 31A (5): 682-685.
- Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of Percentage of Free Serum Prostate-specific Antigen to Improve Specificity of Prostate Cancer Screening. *JAMA* 1995; 274: 1214-1220.
- Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The Effect of Exogenous Testosterone on Total and Free Prostate Specific Antigen Levels in Healthy Young Men. *J Urol* 1996; 156: 438-442.
- Lilja H. Significance of Different Molecular Forms of Serum PSA. *Urol Clin North Amer* 1993; 20 (4): 681-686.
- Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, Lilja H. Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and Ratios. *J Urol* 1995; 154: 1090-1095.
- Ornstein DK, Smith DS, Humphrey PA, Catalona WJ. The Effect of Prostate Volume, Age, total Prostate Specific Antigen Level and Acute Inflammation on the Percentage of Free Serum Prostate Specific Antigen Levels in Men without clinically detectable Prostate Cancer. *J Urol* 1998; 157: 1234-1237.
- Prestigiacomo AF, Stamey TA. Can Free and Total Prostate Specific Antigen and Prostatic Volume Distinguish between Men with Negative and Positive Systematic Ultrasound Guided Prostate Biopsies? *J Urol* 1997; 157: 189-194.
- Stamey TA, Chen Z, Prestigiacomo AF. Serum Prostate Specific Antigen Binding  $\alpha_1$ -Antichymotrypsin: Influence of Cancer Volume, Location and Therapeutic Selection of Resistant Clones. *J Urol* 1994; 152: 1510-1514.
- Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A Complex between Prostate-specific Antigen and  $\alpha_1$ -Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer. *Cancer Res* 1991; 51: 222-226.
- Stenman UH, Leinonen J, Zhang WM. Problems in the Determination of Prostate Specific Antigen. *Eur J Clin Chem Clin Biochem* 1996; 34: 735-740.
- Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a Human Prostate Specific Antigen. *Invest Urol* 1979; 17 (2): 159-163.
- Rafferty B et al. Reference Reagents for Prostate-specific Antigen (PSA): Establishment of the First International Standards for Free PSA and PSA (90:10). *Clin Chem* 2000; 46 (9): 1310-1317.
- Stamey TA et al. Reference Material for PSA: The IFCC Standardization Study. *Clin Biochem* 1998; 31(6):475-481.